Post-Finasteride Syndrome or Pre-Existing Vulnerability? Rethinking Patient Selection. [PDF]
J Cosmet DermatolJournal of Cosmetic Dermatology, Volume 24, Issue 5, May 2025.
Rivetti N.
europepmc +4 more sources
Finasteride adverse effects and post-finasteride syndrome; implications for dentists
Journal of Mind and Medical Sciences, 2016 Finasteride is a 5α-reductase inhibitor widely used in present in the therapeutic approach of androgenic alopecia. Adverse effects consist in variable sign and symptoms, the most common being represented by mental troubles (reduced feeling of life ...
Stana Paunica +7 more
doaj +2 more sources
Finasteride Side Effects and Post-Finasteride Syndrome in Male Androgenic Alopecia
Journal of Mind and Medical Sciences, 2015 Finasteride is in present a relatively frequent prescribed drug for male androgenic alopecia. The adverse effects reported by some patients seem to be notable, consisting of various (physical, mental/ neurological, sexual, etc.) manifestations which are ...
Manea Mirela +3 more
doaj +2 more sources
A Comment on the Post-Finasteride Syndrome.
Int J Trichology, 2018 The post-Finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat hair loss or benign prostatic hyperplasia. While the incidence of persistent sexual, mental, and physical side effects despite quitting finasteride is unknown, and the condition is not recognized by the scientific community, individuals who ...
Rezende HD, Dias MFRG, Trüeb RM.
europepmc +4 more sources
Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. [PDF]
Transl Androl Urol, 2022 Finasteride is widely used in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA). Post-finasteride syndrome (PFS) is a spectrum of persistent symptoms reported by some patients after treatment with finasteride for androgenetic alopecia.
Li X +6 more
europepmc +3 more sources
Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. [PDF]
Int J DermatolABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Gupta AK +3 more
europepmc +2 more sources
Atypical post-finasteride syndrome: A pharmacological riddle.
Indian J Pharmacol, 2016 Finasteride and dutasteride are commonly used 5-alpha reductase inhibitors. While finasteride is a selective inhibitor of 5-alpha reductase Type II, dutasteride inhibits 5- alpha reductase Type I and II. The United States Food and Drug Administration approved the use of finasteride for benign prostatic hypertrophy (BPH) as well as androgenic alopecia ...
Gupta AK, Sharma N, Shukla P.
europepmc +4 more sources
Finasteride Use Does Not Lead to Depression or Suicide: Insights From a Large-Scale Cohort Study and Mendelian Randomization Analysis. [PDF]
J Cosmet DermatolABSTRACT Background Finasteride is widely used in clinical practice to treat androgenetic alopecia (AGA). However, its potential role in increasing the risk of depression and suicidal tendencies among users remains a topic of significant controversy. Patients and Methods Five datasets were used as exposures and ten as outcomes. Mendelian randomization (
Wang J +5 more
europepmc +2 more sources
Finasteride withdrawal induces anxiety‐like behavior and novelty avoidance in adult male rats [PDF]
J NeuroendocrinolAbstract Finasteride, an inhibitor of the enzyme 5alpha‐reductase, prescribed for benign prostatic hyperplasia and androgenetic alopecia, induces a wide variety of side effects during treatment and upon withdrawal, like sexual dysfunction and cognitive and psychological disorders, inducing the so‐called post‐finasteride syndrome (PFS).
Cioffi L +6 more
europepmc +2 more sources
Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness? [PDF]
Skin Appendage Disord, 2019 Post-finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat either hair loss or benign prostatic hyperplasia, independent of age, dosage, or indication. By definition, the condition is characterized by sexual dysfunction, somatic symptoms, and psychological disorders that persist after cessation of ...
Trüeb RM +3 more
europepmc +4 more sources